As the FDA formally recognizes real-world evidence as eligible confirmatory evidence for drug approval, sponsors face a growing imperative to build the data infrastructure, organizational alignment, and analytical capabilities needed to use RWE effectively across the development lifecycle.
Real-world evidence (RWE) has been moving steadily upstream in drug development. With the FDA now explicitly recognizing RWE as eligible confirmatory evidence under its updated single-trial standard, the question is no longer whether RWE belongs in clinical development, but how to build the infrastructure and organizational capabilities to use it effectively.
